LH

367.1300.47%
GA

Garheng Albert Kong

Vice Chairman & Lead Independent Director

Dr. Garheng Albert Kong, M.B.A., M.D., Ph.D., serves as Vice Chairman & Lead Independent Director at Labcorp Holdings Inc. since December 2025 and May 2023 respectively. He joined the firm on December 1, 2013. At Labcorp Holdings Inc. and as Independent Director from December 1, 2013. He is Founder of HealthQuest Capital, which he joined in 2012 and also serves as Managing Partner and Founding Managing Partner. He serves as Director of Eyconis, Inc. since March 2026. He serves as Independent Non-Executive Director of Smith & Nephew plc since September 1, 2025. He serves as Independent Director of Inventurus Knowledge Solutions Limited since August 1, 2025. He serves as Non-Executive Director of OrganOx Limited since April 2025. He serves as Director of Somatus, Inc. since March 2023. He serves as Lead Independent Director of Laboratory Corporation of America Holdings since June 2023. He serves as Director of Nomad Health, Inc. since June 27, 2022. He serves as Independent Non-Executive Director of Xeris Biopharma Holdings, Inc. since October 2021. He serves as Director of Everly Well, Inc. since January 15, 2021. He serves as Non-Executive Director of Perspectum Group plc since April 2020. He serves as Director of Cortendo AB since September 2015. He serves as Director of VirMedica, Inc. since February 19, 2015. He serves as Director of MEDTOX Scientific Inc. since December 2013. He serves as Director of Salveo Specialty Pharmacy, Inc. since December 2012. He serves as Director of Alimera Sciences Limited since 2012. He serves as Director of Aldagen, Inc. since August 2004. He serves as Director of Bardy Diagnostics, Inc., Director of The Hamner Institutes for Health Sciences, Director of TigerConnect, Inc., Non-Executive Director of Lunit Inc. and Director of HealthChannels Inc. He serves on the board of Duke University as a Trustee, Duke University Health System, Dell Children’s Foundation, UT Medicine, UT President’s Commercial Advisory Board and the Austin Healthcare Council. He is a Member of the Executive Board of First Aid Beverages, Inc. and a Member of the Advisory Board of Discovery to Impact. He is an Observer of Magnolia Medical Technologies, Inc. and a Board Observer of Home Hospital Newco, Inc. He served as Independent Director of Venus Concept Inc. from November 2019 to December 2, 2024. He served as Senior Advisor at Ajax Health Management Company, LLC from 2026 to March 2026; at the company, he also served as Chairman of the Board from August 2020 to 2026 and as Director until August 2020. He served as a Director of Alimera Sciences, Inc. from October 2, 2012 to May 17, 2023. He was a Director of CleanSlate Centers, Inc. until 2022. At Strongbridge Biopharma plc, he served as Independent Chairman from July 2020, Lead Independent Director from November 2019 to July 2020 and as Independent Director from September 15, 2015 to November 2019. He was Director of Perspectum Diagnostics Ltd. from April 14, 2020. He was a Director of Alcresta Therapeutics, Inc. from November 10, 2017 to 2019. He was a Director of Melinta Therapeutics, LLC until June 2019. He was Chairman of the Board of Histogenics Corporation until February 22, 2019. He was an Independent Director of Avedro, Inc. from 2018 to November 21, 2019. He was a Director of Castle Biosciences, Inc. from August 13, 2014 to September 2017. He served as Chairman of the Board of Cempra, Inc., where he was employed from September 2006 to August 29, 2013. He was a Director of Cellective Therapeutics, Inc. until August 29, 2013. He was a Director of NovaMin Technology, Inc. until August 29, 2013. He is Founder of Sofinnova Investments, Inc., which he joined on September 8, 2010 and also served as Managing Partner. He was a Director of Asensus Surgical, Inc., which he joined in October 2009. He was a Director of Claris Lifesciences Limited, which he joined in 2012. He was a Director of Proteon Therapeutics, Inc., which he joined on September 6, 2007. He was an Associate of McKinsey & Company, Inc., a General Partner of Intersouth Partners and a Clinical Scientist of Glaxo Wellcome Inc. He was with the medical device start-up, TherOx. He was also a Director of Beacon Therapeutics (USA), Inc., Mycovia Pharmaceuticals, Inc., Trice Medical, Inc., The Council for Entrepreneurial Development, Home Hospital Newco, Inc. and a Member of the Board of Directors of Magnolia Medical Technologies, Inc. He also served as Chairman of Serenex, Inc. and as an Advisor of Sovereigns Capital Management, LLC. He was also a Member of the Board of Directors of Discovery to Impact. A physician, scientist and engineer by training, he has several years' experience investing in innovative healthcare companies and has focused on Biopharmaceutical and Life Sciences. He has served as Chairman on a number of boards. He was named the Top Healthcare Investor of 2025 by GrowthCap, a Top 25 Healthcare Investor of 2024 and 2022 by GrowthCap and a Top 30 Asian American and Pacific Islander Board Member in the U.S. by BoardProspects in 2023. Dr. Kong received a B.S. in Chemical Engineering & Biological Sciences from Stanford University and an M.D. in Biomedical Engineering from Duke University Medical Center, a Ph.D. in Biomedical Engineering from Duke University and an M.B.A. from The Fuqua School of Business.

Positions